Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

Baxter, E. Joanna; Scott, Linda M.; Campbell, Peter J.; East, Clare; Fourouclas, Nasios; Swanton, S; Vassiliou, George S.; Bench, Anthony J.; Boyd, Elaine; Curtin, Natasha Joan; Scott, Mike; Erber, Wendy N.; Green, Anthony

doi:10.1016/s0140-6736(05)71142-9

Cited by 2,516 publications

(1,141 citation statements)

References 35 publications

Supporting

Mentioning

1,041

Contrasting

Unclassified

Order By: Relevance

“…We interrogated the sequencing data in the current study and identified JAK2 p.V617F mutation in nine patients (1.0%, 9/932; Table 2). JAK2 p.V617F is an activating mutation frequently detected in myeloproliferative disorders (MPN), specifically in > 90% of patients with polycythemia vera and in 60% of patients with essential thrombocythemia or idiopathic myelofibrosis [25][26][27]. The JAK2 p.V617F mutation causes constitutive activation of JAK2 kinase and consequently JAK-STAT signaling pathway.…”

Section: Jak2 Pv617f Oncogenic Mutation In 1% Of Nsclcsmentioning

confidence: 99%

Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications

et al. 2017

Genome Med

View full text Add to dashboard Cite

show abstract

Section: Jak2 Pv617f Oncogenic Mutation In 1% Of Nsclcsmentioning

confidence: 99%

Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications

et al. 2017

Genome Med

View full text Add to dashboard Cite

show abstract

“…Recently, several reports have found an identical acquired point mutation in the Janus kinase 2 (JAK2) gene in the blood cells of approximately 60–90% of patients with ET and PV [21,22,23], but not in the blood cells of patients with RT [24, 25]. This mutation is therefore very useful to differentiate primary thrombocytosis from RT.…”

Section: Discussionmentioning

confidence: 99%

Characteristic Changes in Platelet-Large Cell Ratio, Lactate Dehydrogenase and C-Reactive Protein in Thrombocytosis-Related Diseases

2007

View full text Add to dashboard Cite

We examined the clinical usefulness of 3 parameters of routine laboratory tests [platelet-large cell ratio (P-LCR), lactate dehydrogenase (LDH) and C-reactive protein (CRP)] in 84 patients with thrombocytosis-related diseases (reactive thrombocytosis, chronic myeloid leukemia, essential thrombocythemia and polycythemia vera). These thrombocytosis-related diseases were characterized using the 3 parameters P-LCR, LDH and CRP as follows: high P-LCR and high LDH in chronic myeloid leukemia; high CRP in reactive thrombocytosis; slightly high P-LCR and high LDH in essential thrombocythemia and polycythemia vera. For essential thrombocythemia and polycythemia vera, levels of P-LCR and CRP were nearly identical, but the LDH level in essential thrombocythemia was significantly higher than in polycythemia vera. These characteristics of P-LCR, LDH and CRP may be useful for simple and very rough differentiation of the thrombocytosis-related disease mentioned above.

show abstract

“…The project was approved by the Human Research Ethics Committee of University Hospital. The PCR-AE technique was performed according to standard conditions and the product of PCR was visualized on 2% Agarose gel [4]. On the negative samples to the presence of the JAK2 V617F mutation automatic sequencing was done with the aim of identifying possible changes in the exon 12 in the JAK2 gene.…”

Section: Methodsmentioning

confidence: 99%

Evaluation on Thrombotic Events Frequency in JAK2 V617F Positive Patients

Freitas¹,

Guia²,

Nascimento³

et al. 2017

J Hematol Thrombo Dis

View full text Add to dashboard Cite

The Polycythemia Vera is a myeloproliferative neoplasia whose overall incidence is 0.7-2.6 cases per 100.000 inhabitants/year; 92.3% of the patients were positive to the JAK2 V617F mutation (exon 14) and 7.7% were negative also to the mutations on the exon 12. Around 29.16% of the JAK2 V617F positive patients had arterial or venous thrombosis. The percentage of patients with the JAK2 V617F mutation and the frequency of thrombosis in PV JAK2 positive patients demonstrated in our study are according to the data presented in the literature.

show abstract

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

Cited by 2,516 publications

References 35 publications

Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications

Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications

Characteristic Changes in Platelet-Large Cell Ratio, Lactate Dehydrogenase and C-Reactive Protein in Thrombocytosis-Related Diseases

Evaluation on Thrombotic Events Frequency in JAK2 V617F Positive Patients

Contact Info

Product

Resources

About